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H.-J. PriebeA recently published meta-analysis evaluating the role of
perioperative beta-blockade is alarming the medical com-
munity and has reignited the debate regarding whether
patients undergoing non-cardiac surgery beneﬁt from
perioperative beta-blockade.1
This meta-analysis included nine randomized, controlled
trials of beta-blockers initiated before non-cardiac surgery
in 10,529 patients. However, the DECREASE (Dutch Echo-
cardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography) I2 and IV studies3 were excluded from
the meta-analysis following the dismissal of Professor Don
Poldermans by Erasmus University in Rotterdam in 2011
following alleged scientiﬁc misconduct. He had been the
principal investigator of the DECREASE studies.
The meta-analysis reported a 27% increased risk in all-
cause mortality, a 73% increase in non-fatal stroke and a
72% decrease in non-fatal myocardial infarction associated
with perioperative beta-blocker therapy (Table 1). Based on
these ﬁndings and an extrapolation of operations per-
formed in the United Kingdom (UK), the authors proposed
that ignoring the European Society of Cardiology’s (ESC)
recommendations on perioperative beta-blocker therapy4
could prevent up to 10,000 peri-operative deaths each
year in the UK.
The current ESC recommendations include a Class I
recommendation that peri-operative beta-blockade is indi-
cated in patients with known ischaemic heart disease or
myocardial ischaemia according to preoperative stress
testing, or in those undergoing high risk surgery (emergency
or major vascular surgery). The ESC guideline also includes a
class IIa recommendation that peri-operative beta-blockade
be considered in patients undergoing intermediate risk non-
cardiac surgery. The authors of the latest meta-analysis1
now demand an immediate retraction of current guide-
lines on perioperative beta-blocker therapy by the ESC,4 as
well as the American College of Cardiology (ACC) and the
American Heart Association (AHA).5
On what data do the authors base their conclusions and
demands?
In a 2008 meta-analysis by Bangalore et al.,6 there were
almost identical results and conclusions. For the purpose of
assessing the effect of bias on reported outcomes, the au-
thors separately analysed studies with a low or high risk of
bias (indicating high and low scientiﬁc quality respectively)
as deﬁned by the Cochrane Collaboration.7 The DECREASE IBaechelhurst 39, 79249 Merzhausen, Germany
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analysis of all 33 included trials found no increase in over-
all mortality and an 81% decrease in the risk of non-fatal
myocardial infarction (MI) associated with perioperative
beta-blocker therapy. A separate meta-analysis of the 13
low risk of bias trials (which did not include the DECREASE I
study) showed a 28% increased risk in overall mortality and
only a 28% decrease in the risk of non-fatal MI (Table 1). As
there was a major overlap in analyzed trials and because
the large POISE trial8 dominated both meta-analyses, it was
entirely to be expected that the magnitude of associations
between perioperative beta-blocker therapy and mortality
and non-fatal MI in the low risk of bias and “secure” trials
were identical in both studies (Table 1). Surprisingly, how-
ever, whereas Bangalore6 found a strong association be-
tween perioperative beta-blocker therapy and stroke, the
latest meta-analysis by Bouri1 did not (Table 1). This
discrepancy remains difﬁcult to explain and demonstrates
the risk of accepting the results of meta-analyses as ulti-
mate evidence.
Based on the ﬁndings of their 2008 meta-analysis,
Bangalore et al.6 concluded that “because evidence does
not support the use of ß-blocker therapy for the prevention
of perioperative clinical outcomes in patients having non-
cardiac surgery . ß-blockers should not be routinely
used for perioperative treatment of patients undergoing
non-cardiac surgery unless patients are already taking
them for a clinically indicated reason (heart failure, coro-
nary artery disease, previous myocardial infarction).” They
appealed to the ACC/AHA guideline committee to “soften
their stance on perioperative ß blockade until deﬁnitive
evidence shows clear beneﬁt.” They felt that “the use of
perioperative ß blockade as a performance measure, when
there is no robust evidence for improved outcome, was
inappropriate.” Five years later, Bouri et al.1 have arrived
at basically the same conclusion. Accordingly; the new
meta-analysis actually does not provide truly novel
information.
There are several limitations to Bouri’s 2013 meta-
analysis which limit uncritical application into routine clin-
ical practice. First; the value of 1.01 for the lower limit of
the 95% conﬁdence interval (CI) reﬂects borderline statis-
tical signiﬁcance; i.e. questioning the clinical relevance of
the observed statistically signiﬁcant increase in mortality
risk. Second; this meta-analysis (as with all recent meta-
analyses on this topic) is dominated by the large POISE
study8 (Table 1). If the results of the POISE study were
excluded, unequivocal evidence for or against perioperative
beta-blockade would be lacking. The authors acknowledge
that “if the appropriateness of the POISE protocol is
doubted, then the remaining secure data are not sufﬁcient
Table 1. Associations between perioperative beta-blocker therapy
and outcomes.
n RR 95% CI p Value Weight of
POISE study
Mortality
Lancet, 2008 7 1.27 1.01e1.61 0.044 75.2%
Heart, 2013 9 1.27 1.01e1.60 0.04 33.5%
Non-fatal MI
Lancet, 2008 6 0.72 0.59e0.87 0.001 82.3%
Heart, 2013 5 0.73 0.61e0.88 0.001 47.2%
Non-fatal stroke
Lancet, 2008 5 2.16 1.27e3.68 0.004 74.7%
Heart, 2013 5 1.73 1.00e2.99 0.05 64.0%
n, number of low-bias or secure trials; RR, risk ratio; CI, conﬁdence
interval.MI, myocardial infarction; Lancet, 2008 (ref. 6); Heart, 2013
(ref. 1); POISE study, (ref. 8).
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reasons for such doubt to exist. Beta-blockade was started
shortly before surgery, the dose was not titrated to effect,
ﬁxed doses were administered, cardiac and surgical risk
varied between patients and the selected beta-blocker was
exclusively metoprolol. All of these factors might per se
modify outcome (see below).
Third; while everyone would agree that the ﬁndings of
the DECREASE studies2,3 can no longer be trusted, judge-
ment on the scientiﬁc value and clinical impact of each of
the nine trials currently termed “secure” is not so
straightforward. The term “secure” merely designates a
study as not belonging to the group of DECREASE trials. It
does not automatically indicate studies of impeccable sci-
entiﬁc quality. For example; whereas the POBBLE trial9 was
categorized in Bangalore’s 2008 meta-analysis as being a
‘high risk of bias’ trial, it was considered to be a secure
study in Bouri’s 2013 meta-analysis.
Fourth; the claim by Bouri et al. that up to 10,000 lives
per year could be saved in the UK is likely to be an exag-
geration. There is already evidence that adherence to the
ESC and ACC/AHA’s recommendations on perioperative
beta-blocker therapy has declined over the past couple of
years, possibly related to the logistic difﬁculties in imple-
menting efﬁcient beta-blockade in the perioperative period
and to the ﬁndings of the POISE trial.10,11
Finally, and perhaps most importantly, the 2013 meta-
analysis (like all previous ones) included studies with
considerable differences in practice regarding periopera-
tive beta-blockade. Studies varied in; (i) the choice of
beta-blocker (bisoprolol (n ¼ 3), metoprolol (n ¼ 5) and
atenolol (n ¼ 2)); (ii) the timing of preoperative initiation
of beta-blockade (between 37 days and 30 min); (iii) the
duration of postoperative administration (between 5 and
30 days), and (iv) the surgical risk (high, intermediate and
low risk). Information on acute anaemia and blood
transfusion was also lacking. Each (all) of these variables
could modify the effectiveness of perioperative beta-
blocker therapy.
The most commonly used beta-blockers differ in their ß1/
ß2 selectivity ratios (metoprolol, 2.3; atenolol, 4.7;bisoprolol, 13.5).12 There is experimental evidence that
beta-blockade might predispose to stroke by attenuating ß2-
adrenoceptor-mediated cerebral vasodilation.13e15 In
agreement with animal data, in humans the more ß1-se-
lective antagonist bisoprolol was associated with a consid-
erably lower stroke incidence compared with the less ß1-
selective antagonists metoprolol and atenolol.16 Likewise,
atenolol was associated with a considerably lower stroke
incidence when compared to metoprolol.11,17 To my
knowledge, there is only one study (involving 140 cardiac
surgery patients) where beta-blockade was not associated
with a trend for an increased risk of stroke.18 In this study,
the ultra-short acting beta-blocker landiolol was used and
its very high ß1/ß2-selectivity ratio of 250 might have
contributed to this ﬁnding. As a lower incidence of stroke
was also associated with a lower incidence of other severe
adverse events,16 highly ß1-selective beta-blockers may per
se decrease the risk of overall adverse outcomes.
Metoprolol undergoes selective (70e80%) metabolism by
the CYP2D6 isoenzyme of cytochrome P-450. Atenolol and
bisoprolol do not.19,20 In the presence of genetic variations of
the CYP2D6 isoenzyme, variations in elimination half-lives
and plasma concentrations and, in turn, in cardiovascular
effects must be expected to be greater with metoprolol than
with atenolol and bisoprolol. Whereas peak and trough
plasma concentrations of bisoprolol were unaffected by
polymorphisms of the CYP2D6*10 allele, peak and trough
plasma concentrations of metoprolol were twice as high in
patients homozygous for the CYP2D6*10 allele (reﬂecting
poor metabolism of metoprolol), compared to those without
or who were heterozygous for the CYP2D6*10 allele.21 As a
consequence of the higher plasma concentrations in the
poor metabolizers, the increases in heart rate in response to
low and high doses of isoproterenol were signiﬁcantly
blunted. Similarly, polymorphisms of the CYP2D6*4 allele
affected the heart rate of patients taking metoprolol, but not
in those taking atenolol.19 At identical daily doses, mean
plasma concentrations of metoprolol were ﬁve times higher
in poor metabolizers compared to normal metabolizers.22
This was associated with lower heart rates and lower mean
and diastolic blood pressures. These ﬁndings clearly show
that the degree of beta-blockade is far less predictable with
metoprolol than with atenolol or bisoprolol. This would be of
particular clinical relevance when ﬁxed-dose beta-blocker
therapy was started shortly before surgery (as in the POISE
trial). The risk of exaggerated perioperative hypotension and
bradycardia will then be enhanced if the chosen beta-blocker
is metoprolol.
The timing and titration of beta-blockade do not appear
to crucially affect cardioprotection. However, they might
affect all-cause mortality and the risk of stroke, because
acute initiation of ﬁxed-dose beta-blockers may more often
lead to hypotension and bradycardia, both of which are
independent predictors of those outcome variables.8 There
is evidence suggesting that beta-blocker treatment for
longer than one week before surgery is associated with
better outcome than beta-blockade initiated less than one
week preoperatively.23,24 By contrast, a recent analysis
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operative beta-blocker exposure and outcome.11 However,
this analysis included only a small number of patients
receiving beta-blockers within 7 days of surgery. Never-
theless, considering the varying and unpredictable meta-
bolism of beta-blockers and individual patient
responsiveness, it seems advisable to initiate beta-blocker
therapy well ahead of planned surgery, if such a therapy
is medically indicated.
The type of surgery and underlying cardiac risk may also
inﬂuence the effectiveness of perioperative beta-blockade.
Patients undergoing emergency surgery might not beneﬁt
as much as those undergoing elective surgery. This might be
related to a higher incidence of bleeding and hypotension
which were identiﬁed in the POISE study8 as being predictors
of adverse outcome. The risk factors associated with emer-
gency surgerymaybe accentuated by the reduction in cardiac
output reserve caused by beta-blockers. In a large retro-
spective cohort analysis (using a propensity model), periop-
erative beta-blockade was associated with a lower 30-day
mortality and morbidity following major non-cardiac surgery,
but not following vascular surgery.11 In non-vascular surgery,
the extent of underlying cardiac risk inﬂuencedmortality, but
not morbidity. Whereas patients with none or only one
revised cardiac risk index factor did not beneﬁt from beta-
blockade, mortality progressively decreased as the number
of risk factors increased.11 It is difﬁcult to explain the lack of
association between beta-blockade and outcome in vascular
surgery patients who are considered to be at highest risk of
adverse cardiovascular outcome. There has been speculation
that a relative small sample size and the possibilities of
medication and higher level of care not being captured by the
database may explain this somewhat unexpected ﬁnding.
The cardioprotective effect of beta-blockers seems to be
affected by acute surgical anaemia. Overall, major cardiac
events occurred twice as often in patients being treated
with beta-blockers compared to beta-blocker naïve pa-
tients.25 However, this difference was limited to patients
who experienced a 35% decrease in haemoglobin con-
centration from their baseline value. With increasing
amounts of bleeding during vascular surgery, the car-
dioprotective effect of beta-blockade was lost and the risk
of death and/or multi-organ dysfunction syndrome
increased.26 The probability of postoperative stroke asso-
ciated with metoprolol, atenolol and bisoprolol increased
with decreasing postoperative haemoglobin concentra-
tions.16 The threshold postoperative haemoglobin con-
centration below which the probability of stroke started to
increase signiﬁcantly was about 9 g/dL for all beta-
blockers. This is consistent with ﬁndings in humans
where the compensatory cardiac output response to acute
anaemia becomes predominantly heart rate dependent at
haemoglobin concentrations below 9e10 g/dL.27
All beta-blockers will blunt the cardiac output response
to acute anaemia by comparable blockade of ß1-receptors.
However, highly ß1-selective beta-blockers may partly
counteract this cardiodepressant effect by facilitating organ
perfusion through preserved ß2-mediated systemic andregional vasodilation. During low plasma concentrations of
the highly ß1-selective beta-blocker nebivolol, the acute
increase in regional cerebral blood ﬂow in response to
experimentally induced acute haemodilution was preserved
and cerebral tissue oxygenation was not further impaired.
By contrast, higher plasma concentrations blunted the in-
crease in cerebral blood ﬂow and worsened cerebral
oxygenation.15 A possible explanation for the
concentration-dependent differential effects on cerebral
perfusion and oxygenation (despite concentration-
independent comparable depressant effects on cardiac
output and heart rate) may be the increasing afﬁnity of
nebivolol for the vascular ß2-adrenoceptor at the high
plasma concentration, interfering with ß2-mediated cerebral
vasodilation. In corroboration, beta-blockers administered
to anaemic animals at doses that occupy ß2-adrenoceptors
impair cerebral oxygenation.13,14,28 Less ß1-selective beta-
blockers may blunt ß2-mediated cerebral vasodilation
even independent of the haemoglobin concentration. In the
experimental animal, metoprolol increases systemic
vascular resistance and impairs cerebral oxygenation even
at normal haemoglobin concentrations.14 In humans, stroke
risk was higher during metoprolol than during bisoprolol at
nadir postoperative haemoglobin concentrations greater
than 9 g/dL.16
In the POISE study,8 bleeding was associated with an
increased risk of stroke. The association between experi-
mentally impaired cerebral perfusion and oxygenation and
an increased risk of perioperative stroke on one hand, and
anaemia and beta-blockade on the other, suggests that
higher than usually accepted haemoglobin concentrations
and transfusion trigger might beneﬁt beta-blocked patients.
So where do we stand in 2014? The meta-analysis by
Bouri et al.1 does not provide sufﬁcient evidence to justify a
general ban on perioperative beta-blockade in general and
on preoperative initiation of beta-blocker therapy in
particular. The question of which patients might beneﬁt
from perioperative beta-blockade remains unanswered. If
the medical indication for institution of beta-blockade arises
preoperatively, it should be started well before surgery and
the dose should be titrated to effect. Initiation of ﬁxed dose
beta-blockade shortly before surgery must be avoided. The
various experimental and human data suggest that beta-
blockers other than metoprolol should be considered.
Perioperative titration of beta-blockers solely on the basis
of heart rate is potentially dangerous because it may
disguise non-myocardial ischaemic causes of tachycardia
and blunts/suppresses cardiovascular compensatory mech-
anisms. Thus, before administration of beta-blockers, all
non-myocardial ischaemic causes of tachycardia must be
ruled out (e.g., insufﬁcient analgesia, latent hypovolaemia/
hypervolaemia, hypo-/hyperthermia, latent heart failure
and anaemia).
The ESC, ACC and AHA have now reacted to Bouri’s 2013
meta-analysis. On 01 Aug 2013 the ESC issued the following
press release:29 “Further to the publication of a ‘Meta-
analysis of secure randomised controlled trials of ß-blockade
to prevent perioperative death in non-cardiac surgery’1,
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operative Cardiac Risk Assessment and Perioperative Car-
diac Management in Non-Cardiac Surgery, the ESC would
like to state the following: (i) the ESC is currently revising
these guidelines as announced in a previous statement in
March 2013, taking into account this very complex scientiﬁc
issue; (ii) the ESC Board is taking these new ﬁndings very
seriously, keeping patients’ best interests at heart; (iii) the
ESC has convened an urgent task force to decide whether
further actions are required and (iv) the ESC, AHA and ACCF
are collaborating.”
This was followed by a Joint Statement issued by the
ACC, AHA and the ESC on 05 Aug 2013 stating:30 “The
American College of Cardiology, American Heart Association
and the European Society of Cardiology are all in the pro-
cess of completing updated versions of our Guidelines for
Perioperative Care. Our respective writing committees are
undertaking a careful analysis of all relevant validated
studies and always incorporate appropriate new trials and
meta-analyses into our evidence review. In the interim, our
current joint position is that the initiation of beta blockers in
patients who will undergo non-cardiac surgery should not
be considered routine, but should be considered carefully by
each patient’s treating physician on a case-by-case basis.”
This is where we stand at the beginning of 2014.REFERENCES
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